$7.22
+0.41 (+6.02%)
Open$6.87
Previous Close$6.81
Day High$7.45
Day Low$6.60
52W High$11.54
52W Low$4.50
Volume—
Avg Volume35.0K
Market Cap140.99M
P/E Ratio—
EPS$-1.34
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+353.9% upside
Current
$7.22
$7.22
Target
$32.77
$32.77
$27.05
$32.77 avg
$46.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.56M | 16.36M | 16.49M |
| Net Income | -25,397,269 | -919,800 | -1,097,385 |
| Profit Margin | -202.2% | -5.6% | -6.7% |
| EBITDA | -27,817,297 | -1,433,447 | -1,263,705 |
| Free Cash Flow | — | -1,064,720 | -1,173,966 |
| Rev Growth | — | +3.8% | -10.0% |
| Debt/Equity | — | 1.22 | 1.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |